Mereo BioPharma Group/$MREO
1D1W1MYTD1Y5YMAX
Capital at risk
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
- Ticker
- $MREO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 39
- Headquarters
- London, United Kingdom
- Website
- www.mereobiopharma.com
MREO Metrics
BasicAdvanced
$61M
-
-$0.18
0.30
-
Price and volume
Market cap
$61M
Beta
0.3
52-week high
$2.37
52-week low
$0.20
Average daily volume
1.7M
Financial strength
Current ratio
5.884
Quick ratio
5.644
Total debt to equity
0.036
Interest coverage (TTM)
-375.77%
Profitability
EBITDA (TTM)
-32.416
Management effectiveness
Return on assets (TTM)
-42.46%
Return on equity (TTM)
-67.85%
Valuation
Price to book
2.12
Price to tangible book (TTM)
2.13
Price to free cash flow (TTM)
-2.402
Free cash flow yield (TTM)
-41.63%
Free cash flow per share (TTM)
-0.158
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-44.56%
3-year earnings per share growth (CAGR)
-13.47%
10-year earnings per share growth (CAGR)
-31.60%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
Analyst projections of the future price of Mereo BioPharma Group stock.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.